Related references
Note: Only part of the references are listed.Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang et al.
CANCERS (2020)
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Elizabeth L. Christie et al.
NATURE COMMUNICATIONS (2019)
Integrated genomic profiling expands clinical options for patients with cancer
Nike Beaubier et al.
NATURE BIOTECHNOLOGY (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer
Xiao-fang Guo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCBI and ABCG2 transporters
Ying-Fang Fan et al.
CANCER LETTERS (2018)
Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions
Rebecca R. Crawford et al.
DRUG METABOLISM AND DISPOSITION (2018)
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
Shaocong Wu et al.
MOLECULAR CANCER (2018)
Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
Amila K. Nanayakkara et al.
SCIENTIFIC REPORTS (2018)
MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner
Wei Jin et al.
CELL DEATH & DISEASE (2017)
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis
Si Sun et al.
PLOS ONE (2016)
Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
Mohammed A. Osman et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2016)
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
Rishil J. Kathawala et al.
DRUG RESISTANCE UPDATES (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids
Mirjana Kessler et al.
NATURE COMMUNICATIONS (2015)
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
Anna Maria Barbuti et al.
CANCERS (2015)
Dose-Response Analysis Using R
Christian Ritz et al.
PLOS ONE (2015)
Trimmomatic: a flexible trimmer for Illumina sequence data
Anthony M. Bolger et al.
BIOINFORMATICS (2014)
Lapatinib Antagonizes Multidrug Resistance-Associated Protein 1-Mediated Multidrug Resistance by Inhibiting Its Transport Function
Shao-lin Ma et al.
MOLECULAR MEDICINE (2014)
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer
Zhongzhen Guan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity
P-C Lee et al.
ONCOGENE (2013)
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
Mi Young Cha et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer
Daniele Vergara et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2011)
Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer
Feng Li et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
Larry D. Cripe et al.
BLOOD (2010)
A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
Agnieszka Jagiello-Gruszfeld et al.
ONCOLOGY (2010)
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib
Marius Dohse et al.
DRUG METABOLISM AND DISPOSITION (2010)
Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies
Amy J. Chien et al.
CLINICAL CANCER RESEARCH (2009)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Chun-ling Dai et al.
CANCER RESEARCH (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mechanism of activation and inhibition of the HER4/ErbB4 kinase
Chen Qiu et al.
STRUCTURE (2008)
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
Y. Mi et al.
BRITISH JOURNAL OF CANCER (2007)
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents
Helen M. Coley et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells
T Kitazaki et al.
LUNG CANCER (2005)
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples
RT Penson et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
